Dapagliflozin Granted Priority Review for Heart Failure with Reduced Ejection Fraction
January 6, 2020
AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.
Heart Failure
Diabetes an Independent Risk Factor for Heart Failure
January 3, 2020
A new study examined diabetes as an independent predictor of heart failure.
Dapagliflozin Approved to Reduce Hospitalization in Diabetes Patients
October 22, 2019
Reduces risk for heart failure and cardiovascular disease hospitalizations.
AHA: Type 2 diabetes mellitus a risk factor for heart failure
June 14, 2019
Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.
